Cancer of the oral cavity and the oropharynx is the sixth most common tumor entity and the ninth most frequent cause of death worldwide.
1,2 The annual estimated incidence of squamous cell carcinoma (SCC) of the oral cavity is approximately 275 000, and these cases represent more than 90% of all oral cancers.
3,4 However, the diagnosis is determined late in up to 50% of patients and thus the condition is associated with a poor prognosis; the survival rate is approximately 60%, and the estimated recurrence rate is approximately 30% at 5-year follow-up.
5,6 The presence of cervical lymph node metastasis is one of the most important adverse prognostic factors.
7-10 Distant metastases, although rare, are generally considered incurable and therefore alter the therapeutic regimen.
11